Abstract
Keywords
Abbreviations:
BRAF (V-raf murine sarcoma viral oncogene homolog B), CRC (colorectal cancer), CR (conserved regions), ERK (extracellular regulated protein kinases), RPTKs (receptor tyrosine kinases), PDGF (platelet-derived growth factor), Grb2 (growth factor receptor binding protein 2), SOS (son of sevenless), GDP (Guanosine diphosphate), GTP (guanosine triphosphate), MAPK (mitogen-activated protein kinase), PI3K (phosphatidylinositol-3-linase), PKA (protein kinase A), EPAC (exchange protein directly activated by cAMP by cAMP), BIM (Bcl-2-like protein 11), WT (wildtype), PFS (progression-free survival), OS (overall survival), P-PS (post-progression-free survival), EGFR (epidermal growth factor receptor), NCCN (national comprehensive cancer network), VEGF (vascular endothelial growth factor), Beva (Bevacizumab), FOLFOXIRI (fluorouracil + calcium folinate + oxaliplatin + irinotecan), FAD (food and drug administration), CR (complete response), PR (partial response), ASCO (American society of clinical oncology), SD (stable disease), PTEN (phosphatase and tensin homologs), PIK3CA (phosphatidylinositol-3-kinase catalyzed α polypeptide), PD-1/PD-L1 (programmed death-1/ligand-1 programmed death), CTLA-4 (anti-gen-4 associated with cytotoxic T lymphocytes), MSI-H (high microsatellite instability), dMMR (mismatch repair deficient), CIMP (CpG island methylator phenotype), MLH1 (MutL homolog 1), pMMR (mismatch repair proficient), MSS (microsatellite stable), TMB (tumor mutational burden)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerReferences
- Colorectal cancer.Lancet. 2019; 394: 1467-1480
- Promising new agents for colorectal cancer.Curr Treat Options Oncol. 2018; 19: 29
- Targeted therapy for metastatic colorectal cancer.Expert Rev Anticancer Ther. 2018; 18: 991-1006
- KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.Radiol Oncol. 2019; 53: 265-274
- Perspectives in the treatment of RAS or BRAF mutated metastatic colorectal cancer patients.Front Oncol. 2021; 11602596
- Mutations of the BRAF gene in human cancer.Nature. 2002; 417: 949-954
- Sequencing analysis of BRAF mutations in human cancers.Meth Enzymol. 2006; 407: 218-224
- RAF protein-serine/threonine kinases: structure and regulation.Biochem Biophys Res Commun. 2010; 399: 313-317
- Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1.Mol Biol Cell. 2006; 17: 3591-3597
- BRAF mutated colorectal cancer: new treatment approaches.Cancers. 2020; 12
- Regulatory function and expression of rap1gap gene in hematopoietic cells-review.Zhongguo shi yan xue ye xue za zhi. 2009; 17: 1093-1096
- Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.Oncogene. 2008; 27: 7150-7161
- BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.Colorectal Dis. 2013; 15: e711-e718
- BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.Dis Colon Rectum. 2012; 55: 128-133
- BRAF mutation testing in colorectal cancer.Arch Pathol Lab Med. 2010; 134: 1225-1228
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.Cancer. 2014; 120: 2316-2324
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Gut. 2009; 58: 90-96
- Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.Ann Oncol. 2017; 28: 562-568
- K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med. 2008; 359: 1757-1765
National comprehensive cancer network. Clinical practice guidelines in oncology NCCN guidelines. Colon cancer, version 2 2021. https://www.nccnorg/professionals/physician_gls/pdf/colonpdf. 2021.
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.Eur J Cancer. 2015; 51 (Oxford, England: 1990): 587-594
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.Br J Cancer. 2015; 112: 1888-1894
- Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).J Clin Oncol. 2021; 39: 285-294
- Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.N Engl J Med. 2019; 381: 1632-1643
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.Cancer discovery. 2012; 2: 227-235
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.Eur J Cancer. 2014; 50 (Oxford, England: 1990): 57-63
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Lancet Oncol. 2015; 16: 1306-1315
- Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer.J Clin Oncol. 2015; 33: 4032-4038
- Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations.N Engl J Med. 2015; 373: 726-736
- Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma.Clin Cancer Res. 2017; 23: 5339-5348
- Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer.J Clin Oncol. 2015; 33: 4023-4031
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Nature. 2012; 483: 100-103
- Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.Cancer Res. 2012; 72: 779-789
- Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation.Cancer Discov. 2016; 6: 1352-1365
- Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Clin Cancer Res. 2015; 21: 1313-1320
- Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).J Clin Oncol. 2017; 35 (suppl 4): 520
National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines). Colon cancer, version 1. 2018 [EB/OL]. (2018.03.03) https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf 2018.
- Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer.Cancer Discov. 2018; 8: 428-443
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.Nature. 2010; 464: 431-435
- Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study.J Clin Oncol. 2019; 37: 1460-1469
- Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).J Clin Oncol. 2020; 38 (suppl 15): 4001
- LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer.Ann Oncol. 2020; 31 (S242-S3)
- Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.Clin Cancer Res. 2013; 19: 657-667
- Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).J Clin Oncol. 2016; 34 (suppl 15): 3544
- A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer.Cancer Discov. 2017; 7: 610-619
- Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: the phase-II FIRE-4.5 study (AIO KRK-0116).J Clin Oncol. 2021; 39 ((suppl 15): 3502
- KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.Oncol Rep. 2014; 32: 1419-1426
- Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.Mod Pathol. 2014; 27: 135-144
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.Mod Pathol. 2016; 29: 1104-1112
- PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med. 2015; 372: 2509-2520
- Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164.J Clin Oncol. 2020; 38: 11-19
- Pembrolizumab in microsatellite-instability–high advanced colorectal cancer.N Engl J Med. 2020; 383: 2207-2218
- Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer.Front Oncol. 2019; 9: 396
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.Lancet Oncol. 2017; 18: 1182-1191
- A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.Oncol Lett. 2019; 18: 5977-5985
- CCTG CO.26 trial: a phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).J Clin Oncol. 2019; 37 (suppl 4): 481